Summary
We have previously shown that Balb/c mice immunised against syngeneic monoclonal antibodies (mAbs), so that they have anti-idiotypic responses against those mAbs, will clear the mAbs from the circulation as a result of immune complex formation. We report here that with three separate mAbs, this clearance of complexes can result in toxicity to the animals. This was particularly severe with one mAb (NCRC-2), in some cases leading to death. It was not seen with Fab/c or Fab fragments of NCRC-2. This toxic response could be passively transferred with serum, indicating that it was due to formation of immune complexes or to their subsequent clearance. Treatment of mice with cobra venom factor, to reduce complement levels, reduced clearance of complexes but had no effect on toxicity. The anti-histamine pyrilamine did not reduce toxicity. The anti-histamine pyrilamine did not reduce toxicity. This is one of only a few situations in which an anti-(mouse antibody)response has been reported to be potentially dangerous, and is particularly remarkable since it occurs as a result of such a limited anti-antibody response.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- mAb:
-
monoclonal antibody
- CEA:
-
carcinoembryonic antigen
- PBS:
-
phosphate-buffered saline, pH 7.2
References
Azuma J, Kurimoto T, Tsuji S, Mochizuki N, Funjinaga S, Matsumoto Y, Masuho Y (1991) Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity. J Immunother 10:278–285
Brown PS, Parenteau GL, Dirbas FM, Garsia RJ, Goldman CK, Bukowski MA, Junghans RP, Queen C, Hakimi J, Benjamin WR, Clark RE, Waldman TA (1991) Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 88:2663–2667
Demignot S, Pimm MV, Baldwin RW (1990) Comparison of biodistribution of 791T/36 monoclonal antibody and its Fab/c fragment in Balb/c mice and nude mice bearing human tumour xenografts. Cancer Res 50:2936–2942
Dillman R (1990) Human antimouse and antiglobulin response to monoclonal antibodies. Antibody Immunoconj Radiopharmacol 3:1–15
Embleton MJ, Gunn B, Byers VS, Baldwin RW (1981) Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line. Br J Cancer 43:582–587
Fraker PJ, Speck JC (1978) Protein and cell membrane iodination with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril. Biochem Biophys Res Commun 80:849–857
Furness PN, Turner DR (1988) Chronic serum sickness glomerulonephritis: removal of glomerular antigen and electron-dense deposits is largely dependent on plasma complement. Clin Exp Immunol 74:126–130
Hird V, Verhoeyen M, Badley RA, Price D, Snook D, Kosmas C, Gooden C, Bamias A, Meares C, Lavender JP, Epenetos AA (1991) Tumour localization with a radioactively labelled reshaped human monoclonal antibody. Br J Cancer 64:911–914
Kaminski MS, Kitamura K, Maloney DG, Levy R (1987) Idiotype vaccination against murine B cell lymphoma. Inhibition of tumour immunity by free idiotype protein. J Immunol 138:1289–1296
Khazaeli MB, Saleh MN, Liu TP, Meredith RF, Wheeler RH, Baker TS, King D, Secher D, Allen L, Rogers K, Colcher D, Schlom J, Shochat D, LoBuglio AF (1991) Pharmacokinetics and immune response of131I-chimeric mouse/human B72.3 (human γ4) monoclonal antibody in humans. Cancer Res 51:5461–5466
Meredith RF, LoBuglio AF, Plott WE, Orr RA, Brezovich IA, Russell CD, Harvey EB, Yester MV, Wagner AJ, Spencer SA, Wheeler RH, Saleh MN, Rogers KJ, Polansky A, Salter MM, Khazaeli MB (1991) Pharmacokinetics, immune response and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,K 17-1A monoclonal antibody. J Nucl Med 32:1162–1168
Morgan BP (1990) Complement-clinical aspects and relevance to disease. Academic Press, London
Neuberger MS, Rajewsky K (1981) Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol 11:1012–1016
Pimm MV, Baldwin RW (1990) Syngeneic anti-idiotypic antibody prevents localization of a murine monoclonal antibody in human tumour xenografts. Eur J Cancer 26:567–568
Pimm MV, Perkins AC, Durrant LG, Baldwin RW (1988) A rat model for imaging the effect of anti-mouse antibody responses on the biodistribution of radiolabelled mouse monoclonal antibodies. Eur J Nucl Med 14:507–511
Pimm MV, Durrant LG, Baldwin RW (1989) The influence of syngeneic anti-idiotypic antibody on the biodistribution of an antitumour monoclonal antibody in Balb/c mice. Int J Cancer 43:147–151
Price MR, Edwards S, Jacobs E, Pawluczyk IZA, Byers VS, Baldwin RW (1987) Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEA. Cancer Immunol Immunother 25:10–15
Price MR, Sekowski M, Tendler SJB (1991) Purification of anti-epithelial mucin monoclonal antibodies by epitope affinity chromatography. J Immunol Methods 139:83–90
Steis RG, Carrasquillo JA, McCabe R, Bookman MA, Reynolds JC, Larson SM, Smith JW, Clark JW, Dailey V, Vecchio SD, Shuke N, Pinsky CM, Urba WJ, Haspel M, Perentesis P, Paris B, Longo DL, Hanna MG (1990) Toxicity, immunogenicity and tumour radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol 8:476–490
Van Kroonenburgh MJPG, Pauwels EKJ (1988) Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Commun 9:919–930
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pimm, M.V., Gribben, S.J. Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice. J Cancer Res Clin Oncol 119, 41–45 (1992). https://doi.org/10.1007/BF01209486
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01209486